explore -WSS

explore

author：Wikipedia 2025-09-29 10:31:32 - browse：31877

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Digital health: a case of mistaken identity

focus

WSS

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Study finds gene variants tied to breast cancer risk in Black women

ASCO eve: Let’s set the table for this year's meeting

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Questions and answers about ramping up H5N1 bird flu vaccine

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

What does generative AI mean for health care? We asked experts

H5N1 bird flu outbreak: Second human case reported, in Michigan

New air purifier tech could be key to improving indoor air quality

Investigation reveals sickle cell patients pressured into sterilizations

Peter Hotez and the public health issue of online harassment

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Activists slam private health insurers over coverage restrictions

Democratic lawmaker calls for 'well

entertainment

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Why workplace violence is so common in health care

Fentanyl is making it harder to start addiction treatment

explore

focus

focus

Wikipedia